These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 22040163)
21. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Abella JV; Park M Am J Physiol Endocrinol Metab; 2009 May; 296(5):E973-84. PubMed ID: 19240253 [TBL] [Abstract][Full Text] [Related]
23. Receptor tyrosine kinase inhibitors in thyroid cancer. Castellone MD; Carlomagno F; Salvatore G; Santoro M Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1023-38. PubMed ID: 19041829 [TBL] [Abstract][Full Text] [Related]
24. Flavonoids as RTK inhibitors and potential anticancer agents. Teillet F; Boumendjel A; Boutonnat J; Ronot X Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331 [TBL] [Abstract][Full Text] [Related]
25. Defective downregulation of receptor tyrosine kinases in cancer. Bache KG; Slagsvold T; Stenmark H EMBO J; 2004 Jul; 23(14):2707-12. PubMed ID: 15229652 [TBL] [Abstract][Full Text] [Related]
26. Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2. Himanen JP; Henkemeyer M; Nikolov DB Nature; 1998 Dec; 396(6710):486-91. PubMed ID: 9853759 [TBL] [Abstract][Full Text] [Related]
27. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Shimizu M; Adachi S; Masuda M; Kozawa O; Moriwaki H Mol Nutr Food Res; 2011 Jun; 55(6):832-43. PubMed ID: 21538846 [TBL] [Abstract][Full Text] [Related]
28. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Ghosh S; Marrocco I; Yarden Y Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398 [TBL] [Abstract][Full Text] [Related]
29. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Valiathan RR; Marco M; Leitinger B; Kleer CG; Fridman R Cancer Metastasis Rev; 2012 Jun; 31(1-2):295-321. PubMed ID: 22366781 [TBL] [Abstract][Full Text] [Related]
30. Kinases as targets in the treatment of solid tumors. Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351 [TBL] [Abstract][Full Text] [Related]
31. Energetics of Src homology domain interactions in receptor tyrosine kinase-mediated signaling. Ladbury JE; Arold ST Methods Enzymol; 2011; 488():147-83. PubMed ID: 21195228 [TBL] [Abstract][Full Text] [Related]
32. Receptor tyrosine kinase inhibitors as anti-angiogenic agents. Kim DW; Lu B; Hallahan DE Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247 [TBL] [Abstract][Full Text] [Related]
33. The ErbB/HER receptor protein-tyrosine kinases and cancer. Roskoski R Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434 [TBL] [Abstract][Full Text] [Related]
34. Autoinhibitory mechanisms in receptor tyrosine kinases. Hubbard SR Front Biosci; 2002 Feb; 7():d330-40. PubMed ID: 11815286 [TBL] [Abstract][Full Text] [Related]
35. The N-terminal globular domain of Eph receptors is sufficient for ligand binding and receptor signaling. Labrador JP; Brambilla R; Klein R EMBO J; 1997 Jul; 16(13):3889-97. PubMed ID: 9233799 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment. Roussidis AE; Karamanos NK In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890 [TBL] [Abstract][Full Text] [Related]
37. Structural studies of full-length receptor tyrosine kinases and their implications for drug design. Bajinting A; Ng HL Adv Protein Chem Struct Biol; 2021; 124():311-336. PubMed ID: 33632469 [TBL] [Abstract][Full Text] [Related]
38. Mechanisms of receptor tyrosine kinase activation in cancer. Du Z; Lovly CM Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648 [TBL] [Abstract][Full Text] [Related]
39. Receptor tyrosine kinases as therapeutic targets in cancer. Hynes NE Discov Med; 2005 Oct; 5(29):483-8. PubMed ID: 20704847 [TBL] [Abstract][Full Text] [Related]